Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company adopted a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Local breweries might have an easier path to sell their products. Thursday, lawmakers overwhelmingly passed LB 113, allowing small business breweries self-distribute their products without a middle ...

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process ...

$KROS insiders have traded $KROS stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales. Here’s a ...

Shares of KROS stock opened at $9.55 on Friday. The firm has a 50-day moving average of $11.10 and a 200-day moving average of $33.64. Keros Therapeutics has a one year low of $9.41 and a one year ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $25.00. The company’s shares closed ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...